ライフサイエンスコーパス: rotavirus

1 (95% CI, 64%-93%) against moderate to severe rotavirus.

2 t protection through reduced transmission of rotavirus.

3 other enteropathogens, with the exception of rotavirus.

4 hea, and controls were children negative for rotavirus.

5 000 for Cryptosporidium, and 1 in 118000 for rotavirus.

6 thogens, which include influenza viruses and rotaviruses.

7 nual changes in hospitalizations for AGE and rotavirus; 2012 was excluded as a transition year.

8 Rotavirus, a leading cause of severe gastroenteritis and

9 In the Africa Region, the rotavirus AF declined from 54.8% (95% CI, 48.3%-61.5%) i

10 tions and emergency department visits due to rotavirus AGE were reduced by a median of 67% overall an

11 birth cohort, it will avert 54 000 cases of rotavirus and 281 deaths in children aged <5 years.

12 assess the impact of vaccine introduction on rotavirus and acute gastroenteritis (AGE) hospitalizatio

13 cination on hospitalizations and deaths from rotavirus and all-cause acute gastroenteritis (AGE) duri

14 irus vaccine introduction, seasonal peaks of rotavirus and all-cause AGE were dwarfed.

15 ubstantially decreased hospitalizations from rotavirus and all-cause AGE.

16 Knowledge of innate susceptibility to rotavirus and norovirus can lead to improved understandi

17 Mirpur, Dhaka) as part of the performance of rotavirus and oral polio vaccines in developing countrie

18 Stools were tested for rotavirus and sera for antirotavirus immunoglobulins by

19 ed on enterocytes are proposed receptors for rotaviruses and can be measured in saliva.

20 haracterization of the confrontation between rotaviruses and their host cells has allowed us to learn

21 ubella, yellow fever, Japanese encephalitis, rotavirus, and invasive bacterial diseases.

22 among children whose stool was positive for rotavirus antigen (cases) and children whose stool was n

23 was made by enzyme immunoassay detection of rotavirus antigen in stool specimens.

24 talized for AGE have stool sample tested for rotavirus antigen, was used to assess trends in rotaviru

25 Norovirus and rotavirus are prominent enteric viruses responsible for

26 Rotaviruses are known to recognize human histo-blood gro

27 athogens Campylobacter, Cryptosporidium, and rotavirus as conservative risk proxies for infections vi

28 sing children with AGE who test negative for rotavirus as controls for the rotavirus-positive cases.

29 e gastroenteritis (AGE) hospitalizations and rotavirus-associated hospitalizations during the prevacc

30 We studied trends in admissions specific to rotavirus at one hospital that had undertaken active rot

31 Using rotavirus binding and blocking assays, this study elucid

32 Fecal specimens were tested for rotavirus by enzyme immunoassay and genotyped.

33 GE had their stools collected and tested for rotavirus by enzyme immunoassay.

34 garis (PV), as well as B cells responding to rotavirus capsid protein VP6.

35 t per DALY averted was $10, and the cost per rotavirus case averted was $1.

36 Based on 204 rotavirus case patients and 601 test-negative controls a

37 rmed a case-control study of VE by comparing rotavirus case patients with test-negative controls.

38 ased diarrheal surveillance used to identify rotavirus cases but who test negative for rotavirus (tes

39 Vaccination among laboratory-confirmed rotavirus cases was compared with rotavirus-negative AGE

40 fectiveness was 59% (95% CI, 4%-83%) against rotavirus caused by G2P, the most common (37%) circulati

41 ore susceptible to infections from P[8]-type rotaviruses compared with nonsecretors (95% CI, 8.3-85.0

42 nt for more than half the global deaths from rotavirus, concerns remain about the performance of oral

43 confidence interval, 74.3%, 83.0%) >/=2-dose rotavirus coverage among participants eligible for publi

44 or approximately half (49%) of all estimated rotavirus deaths in 2013.

45 Globally, we estimated that the number of rotavirus deaths in children <5 years of age declined fr

46 In 2013, an estimated 47 100 rotavirus deaths occurred in India, 22% of all rotavirus

47 tavirus deaths occurred in India, 22% of all rotavirus deaths that occurred globally.

48 of children with AGE who tested positive for rotavirus declined from 53% (645/1223) in prevaccine yea

49 VE estimate is consistent with the observed rotavirus decrease and with efficacy estimates from else

50 acity that is characteristic of RNA viruses, rotavirus dedicates substantial resources to avoiding th

51 The predicted annual rotavirus detection rate from these studies declined sli

52 n less than 2 y of age presenting with acute rotavirus diarrhea (ARD) through March 31, 2011.

53 understand variables contributing to risk of rotavirus diarrhea (RVD).

54 RV5 were similarly effective against severe rotavirus diarrhea caused by a heterotypic strain in Gua

55 o determine the effectiveness of RV1 against rotavirus diarrhea hospitalization using a case-control

56 t of nutritional status on susceptibility to rotavirus diarrhea is not well understood.

57 Against rotavirus diarrhea of all severity, the adjusted 2-dose

58 E of 2 RV1 doses against hospitalization for rotavirus diarrhea was 57% (95% confidence interval, 14%

59 patients (children with laboratory-confirmed rotavirus diarrhea) and nonrotavirus "test-negative" dia

60 Assuming a 1% attack rate for severe rotavirus diarrhea, a 3% attack rate for severe nonrotav

61 tavalent rotavirus vaccine (RotaTeq) against rotavirus diarrhea.

62 immunization program to reduce the burden of rotavirus disease (documented to cause 38% of acute gast

63 Rotavirus vaccine is effective in preventing rotavirus disease in Rwandan children who began their ro

64 In Peru, incidence of rotavirus disease was relatively higher during the secon

65 use, both RV1 and RV5 are effective against rotavirus disease, supporting the World Health Organizat

66 gA responses associated with protection from rotavirus disease.

67 and tended to be greater against more severe rotavirus disease.

68 ding a novel approach to vaccination against rotavirus disease.

69 We show that binding of the rotavirus-encoded non-structural protein NSP2 to viral s

70 VH1-46 mAbs previously isolated from PV and rotavirus-exposed individuals indicates that cross-react

71 isms prevent the onset of autoimmunity after rotavirus exposure.

72 rcentage of hospital admissions positive for rotavirus fell from 45% in the prevaccine period to 25%

73 rcentage of hospital admissions positive for rotavirus fell from 48% in the prevaccine period to 28%

74 ength of naturally acquired immunity against rotavirus gastroenteritis (RVGE), mirroring vaccine unde

75 first episode of laboratory-confirmed severe rotavirus gastroenteritis (Vesikari score, >/=11) beginn

76 ine, had an efficacy of 66.7% against severe rotavirus gastroenteritis among infants in Niger.

77 cacy analysis, there were 31 cases of severe rotavirus gastroenteritis in the vaccine group and 87 ca

78 Each year, rotavirus gastroenteritis is responsible for about 37% o

79 ce interval [CI], 31%-91%) effective against rotavirus gastroenteritis requiring hospitalization or a

80 Serum Institute of India) to prevent severe rotavirus gastroenteritis.

81 al stools, and 344 (19.8%) children ever had rotavirus gastroenteritis.

82 e found 2 significant positive interactions: rotavirus + Giardia (odds ratio (OR) = 23.91, 95% confid

83 P[6] rotaviruses have been circulating with a high prevalence

84 wo-dose VE was 79% (95% CI, 62%-88%) against rotavirus hospitalization and 84% (95% CI, 64%-93%) agai

85 ctions of 40%, 46%, and 69% in the number of rotavirus hospitalizations among infants in 2013, 2014,

86 We performed active surveillance for rotavirus hospitalizations at the largest hospital in Za

87 n infants <1 year who accounted for 84.4% of rotavirus hospitalizations prior to vaccine introduction

88 Armenian children and substantially reduced rotavirus hospitalizations shortly after introduction.

89 ough indirect protection; overall in year 3, rotavirus hospitalizations were reduced by 69% among chi

90 ectiveness (VE) of 2 RV1 doses in preventing rotavirus hospitalizations.

91 avirus antigen, was used to assess trends in rotavirus hospitalizations.

92 hat is believed to play an important role in rotavirus host susceptibility and host range.

93 ultures from multiple individuals with human rotavirus (HRV) and assessed the host epithelial respons

94 bella antibody seroconversion and evaluating rotavirus IgA/IgG seroresponses in MR + HRV recipients.

95 odds ratio [OR], 0.77; P = .002) and lack of rotavirus immunoglobulin A (IgA) seroconversion (OR, 1.9

96 rial who were seronegative at baseline, anti-rotavirus immunoglobulin A seroconversion rates after 3

97 mented routine childhood vaccination against rotavirus in 2007.

98 children with diarrhoea testing positive for rotavirus in almost every age group.

99 We assessed vaccine effectiveness against rotavirus in Guatemala, where both the monovalent (RV1;

100 the benefits of routine vaccination against rotavirus in low-income settings.

101 of admissions to hospital for diarrhoea and rotavirus in Rwanda fell substantially after rotavirus v

102 increasing global importance of genotype G9 rotaviruses in humans and pigs.

103 ric viral pathogens, including norovirus and rotavirus, in both preventing and curing infection.

104 In low-resource populations with high rotavirus incidence, large-scale vaccination across a wi

105 te recruitment, and biliary injury in rhesus rotavirus-induced BA.

106 isk of rotavirus infection and all P[8]/P[4] rotavirus infected children were secretors.

107 iral response is specific to the pancreas of rotavirus-infected mice, similar to the autoimmunity ass

108 The rapid declines in rotavirus infection and AGE in vaccinated and unvaccinat

109 ses were found to correlate with the risk of rotavirus infection and all P[8]/P[4] rotavirus infected

110 Rotavirus infection and disease were common, but with si

111 rstand naturally acquired protection against rotavirus infection and RVGE.

112 omposing the incidence rate into the rate of rotavirus infection and the risk of RVGE given infection

113 od of a 12-month increment, and detection of rotavirus infection by enzyme immunoassay in at least 10

114 multicountry birth cohort study, we describe rotavirus infection in the first 2 years of life in site

115 Rotavirus infection is one of the most common causes of

116 host genetic susceptibility to norovirus and rotavirus infection may be strain specific.

117 As childhood nutrition improves worldwide, rotavirus infection may remain a public health challenge

118 We find that MDA5 activity limits rotavirus infection not only through the induction of an

119 s crucial for the immune response to enteric rotavirus infection, a proposed etiological agent for T1

120 in intestinal epithelial cells and restricts rotavirus infection.

121 e associated with partial protection against rotavirus infection.

122 er T1D risk exhibit reduced activity against rotavirus infection.

123 estimated the impact on laboratory-confirmed rotavirus infections and hospitalizations for all-cause

124 ed to evaluate potential association between rotavirus infections and human HBGA phenotypes.

125 have been observed for laboratory-confirmed rotavirus infections during the 2014-2015 season.

126 o age-related, antibody-independent risk for rotavirus infections to cause RVGE.

127 ving childhood vaccines for pneumococcal and rotavirus infections while greatly expanding coverage of

128 rstood, but in analogy to Gardia lamblia and rotavirus infections, secondary lactose maldigestion (LM

129 mechanisms that host cells employ to prevent rotavirus invasion and the countermeasures that these vi

130 Rotavirus is a leading cause of death due to diarrhea am

131 Rotavirus is a leading cause of dehydrating diarrhea and

132 and reduces pathogenicity in mice.IMPORTANCE Rotavirus is the leading cause of diarrhea in humans.

133 Rotavirus is the world's leading cause of childhood diar

134 Rotaviruses, like most viruses that lack membranes of th

135 ns, and monitor vaccine impact, we estimated rotavirus mortality for children <5 years of age from 20

136 Continued monitoring of rotavirus mortality rates and deaths through rotavirus s

137 hia coli (EPEC, n = 21), norovirus (n = 21), rotavirus (n = 15), sapovirus (n = 9), and Salmonella (n

138 -confirmed rotavirus cases was compared with rotavirus-negative AGE controls.

139 ine (33/44 [73%] unvaccinated) compared with rotavirus-negative children (81/136 [59%] unvaccinated)

140 Rotavirus nonstructural protein 4 (NSP4) is an endoplasm

141 Rotavirus, norovirus genogroup II, Cryptosporidium, and

142 ere >88% for Shigellaspp.,Campylobacterspp., rotavirus, norovirus genotype 1/2 (GI/GII), and adenovir

143 health burdens for Giardia, Cryptosporidium, rotavirus, norovirus, and adenovirus infections resultin

144 Moreover, rotavirus NSP1 (nonstructural protein 1) employs a pLxIS

145 come countries where >90% global deaths from rotavirus occur.

146 tolerated) to parenteral P2-VP8-P[8] subunit rotavirus or placebo injection.

147 Infectious rotavirus particles are triple-layered, icosahedral asse

148 The properties of rotavirus particles make it possible to determine molecu

149 the following question: what fraction of the rotavirus particles that penetrate into the cell make ne

150 ted randomly among binding locations, inside rotavirus particles.

151 C viruses, herpes simplex virus, norovirus, rotavirus, parvovirus, and Epstein-Barr virus.

152 e likely to stimulate new research into both rotavirus pathogenesis and endotoxemia.

153 sis underlying inter-segment interactions in rotaviruses, paving the way for delineating similar RNA-

154 evaluate the efficacy of a live, oral bovine rotavirus pentavalent vaccine (BRV-PV, Serum Institute o

155 t negative for rotavirus as controls for the rotavirus-positive cases.

156 Rotavirus-positive children were significantly less like

157 The rotavirus positivity rate declined from 40.1% (449/1121)

158 est reduction was noted in infants, with the rotavirus positivity rate in this age group declining fr

159 Rotavirus prevalence is estimated to decline by 10.5% wi

160 ich are a common beginning in articles about rotaviruses, reflects the fact that these viruses have e

161 ovel insights into the mechanisms underlying rotavirus regulation of different interferons and are li

162 Rotavirus remained the leading etiology (overall weighte

163 Rotavirus remained the leading etiology of acute watery

164 Among 146 children enrolled in 2015, rotavirus remained the leading etiology of diarrhea requ

165 act of vaccine introduction in this setting, rotavirus remained the leading etiology of diarrhea requ

166 sulted in enhanced susceptibility of mice to rotavirus replication.

167 "Rotaviruses represent the most important etiological age

168 ugh the identified human G9P[19] and G9P[13] rotaviruses represented minority strains, the repeated d

169 of 2-3 doses of a rotavirus vaccine against rotavirus requiring emergency department visit or hospit

170 -specific inter-segment interactions between rotavirus RNAs, taking place in a complex RNA- and prote

171 Rhesus rotavirus (RRV) can also lead to biliary atresia (a neon

172 In neonatal mice, rhesus rotavirus (RRV) can induce biliary atresia (BA), a disea

173 The murine model of BA, employing rhesus rotavirus (RRV), parallels human disease and has been us

174 Rotavirus (RV) causes significant morbidity and mortalit

175 Rotavirus (RV) is the leading cause of diarrhea-related

176 Temperature-sensitive (ts) mutants of simian rotavirus (RV) strain SA11 have been previously created

177 Hepatitis E virus (HEV), rotavirus (RV), and astrovirus (AstV) are important path

178 Rotavirus (RV)-associated infections account for high nu

179 Group A rotaviruses (RVA) are a significant cause of pediatric g

180 Rotaviruses (RVs) can evolve through the process of reas

181 The regulation by rotaviruses (RVs) of antiviral pathways mediated by mult

182 pe belongs to the P[II] genogroup of group A rotaviruses (RVs).

183 Declines were most prominent during the rotavirus season (May-October) and among infants <1 year

184 s, with greater declines observed during the rotavirus season compared with non-rotavirus season mont

185 ed mortality and hospitalizations during the rotavirus season months were considerably diminished in

186 uring the rotavirus season compared with non-rotavirus season months.

187 admissions in 2015, as well as delay of the rotavirus season.

188 us, kobuvirus, parechovirus, parvovirus, and rotavirus sequences were frequently detected but were no

189 D45(-) PCs during ageing and the presence of rotavirus-specific clones entirely within the CD19(-) PC

190 Rotavirus specifically infects the intestinal epithelial

191 participants who met study criteria and had rotavirus stool testing performed and vaccine status con

192 n both in vitro and in vivo In addition many rotavirus strains are resistant to the actions of differ

193 Because >60 rotavirus strains have been reported worldwide, concerns

194 ains, the repeated detection of porcine-like rotavirus strains in Taiwanese children over time justif

195 nding that the sequence is specific to those rotavirus strains that cause obstructive cholangiopathy.

196 s at one hospital that had undertaken active rotavirus surveillance from 2011 to 2014.

197 World Health Organization (WHO)-coordinated rotavirus surveillance network between 2008 and 2013 tha

198 rotavirus mortality rates and deaths through rotavirus surveillance will aid in monitoring the impact

199 Costs did not differ by rotavirus test result, but were significantly higher for

200 The use of rotavirus test-negative controls offers an efficient and

201 fy rotavirus cases but who test negative for rotavirus (test-negative controls) can be considered a s

202 re, we focus on the transmission dynamics of rotavirus, the main diarrheal disease in infants and you

203 We searched PubMed using the keyword "rotavirus" to identify studies that met each of the foll

204 infections (respiratory syncytial virus and rotavirus) to illustrate this problem.

205 Although the potential health benefits of rotavirus vaccination are huge in low-income African cou

206 separately, we propose a design to estimate rotavirus vaccination coverage using controls from a rot

207 The public health impact of rotavirus vaccination in African settings with a high hu

208 bing the impact and effectiveness of routine rotavirus vaccination in developing countries that were

209 This supports broader implementation of rotavirus vaccination in low-income countries where >90%

210 ts that could result in countries that adopt rotavirus vaccination into their national immunization p

211 We summarize the impact of rotavirus vaccination on hospitalizations and deaths fro

212 roups within 1 year of introducing an infant rotavirus vaccination program are far greater than expec

213 The two-dose HRV rotavirus vaccination program significantly reduced medi

214 lowing implementation of the Quebec, Canada, rotavirus vaccination program.

215 In countries with effective rotavirus vaccination programs, disease due to that path

216 st 2 years of life in sites with and without rotavirus vaccination programs.

217 Rotavirus vaccination reduces childhood hospitalization

218 d encourage other countries to adopt routine rotavirus vaccination to reduce the health burden of sev

219 nfants (aged 6 to <8 weeks, without previous rotavirus vaccination).

220 In addition to rotavirus vaccination, actions to improve nutrition stat

221 ay be required to obtain the full benefit of rotavirus vaccination, including indirect effects.

222 itionally, the effectiveness of programmatic rotavirus vaccination, including possible indirect effec

223 n children associated with implementation of rotavirus vaccination.

224 o before and 7 years after implementation of rotavirus vaccination.

225 ve of the beneficial public health impact of rotavirus vaccination.

226 sed on samples from a country with universal rotavirus vaccination.

227 e significantly less likely to have received rotavirus vaccine (33/44 [73%] unvaccinated) compared wi

228 tiveness of a two-dose schedule of the human rotavirus vaccine (HRV; Rotarix) given early at 6 and 10

229 vaccine effectiveness (VE) of a pentavalent rotavirus vaccine (RotaTeq) against rotavirus diarrhea.

230 a surveillance to evaluate monovalent G1P[8] rotavirus vaccine (RV1) efficacy and understand variable

231 Botswana introduced monovalent G1P rotavirus vaccine (RV1) in July 2012, providing one of t

232 ndomized controlled trial of monovalent oral rotavirus vaccine (RV1).

233 (HEU) African infants receiving pentavalent rotavirus vaccine (RV5) in a clinical trial.

234 Pentavalent rotavirus vaccine (RV5) was introduced into the Israeli

235 To facilitate decision making on rotavirus vaccine adoption by countries, help donors pri

236 Effectiveness of 2-3 doses of a rotavirus vaccine against rotavirus requiring emergency

237 declined from 54.8% (95% CI, 48.3%-61.5%) in rotavirus vaccine age-ineligible children to 20.0% (95%

238 Plasma IgA levels specific for antigens in rotavirus vaccine and oral polio vaccine containing poli

239 nd immunogenicity of the P2-VP8-P[8] subunit rotavirus vaccine at different doses in South African to

240 We sought to determine monovalent rotavirus vaccine cost-effectiveness in Malawi, one of A

241 uncan Steele discuss the evidence supporting rotavirus vaccine deployment in Asian countries.

242 l study at 6 public sector sites to estimate rotavirus vaccine effectiveness (VE) in age-eligible chi

243 We sought to evaluate rotavirus vaccine effectiveness (VE) in this setting.

244 Rotavirus vaccine efficacy is lower in low-income countr

245 MA) to identify observational evaluations of rotavirus vaccine impact among children <5 years of age

246 rotavirus in Rwanda fell substantially after rotavirus vaccine implementation, including among older

247 pilot introduction of the Rotarix live, oral rotavirus vaccine in all public health facilities in Lus

248 Together with the demonstrated impact of rotavirus vaccine in reducing population hospitalization

249 countries in sub-Saharan Africa to introduce rotavirus vaccine into its national immunization program

250 in the Newly Independent States to introduce rotavirus vaccine into its national immunization program

251 ome African country to introduce pentavalent rotavirus vaccine into its routine national immunisation

252 recommendation that all countries introduce rotavirus vaccine into their national immunization progr

253 Pre-rotavirus vaccine introduction (2009-2011) and post-rota

254 us vaccine introduction (2009-2011) and post-rotavirus vaccine introduction (2013-2014) periods were

255 of diarrhea requiring hospitalization after rotavirus vaccine introduction in Africa.

256 Following rotavirus vaccine introduction, seasonal peaks of rotavi

257 hospitalizations, temporally associated with rotavirus vaccine introduction, was observed in children

258 ins poorly characterized, particularly after rotavirus vaccine introduction.

259 ted to children 7-18 weeks of age at time of rotavirus vaccine introduction.

260 n-hospital morbidity and mortality following rotavirus vaccine introduction.

261 te watery diarrhea despite a clear impact of rotavirus vaccine introduction.

262 Rotavirus vaccine is effective in preventing rotavirus d

263 Rotavirus vaccine is recommended for routine use in all

264 We aimed to assess the impact of the rotavirus vaccine program and estimate vaccine effective

265 The rotavirus vaccine program is highly cost-effective.

266 A monovalent rotavirus vaccine remains effective against a broad rang

267 n and immune activation were correlated with rotavirus vaccine responses in 68 human immunodeficiency

268 disease in Rwandan children who began their rotavirus vaccine series from 7 to 18 weeks of age.

269 Togo introduced monovalent rotavirus vaccine starting 19 June 2014.

270 Adding rotavirus vaccine to the national schedule costs Malawi

271 Among 181 Pakistani infants in a G1P[8] rotavirus vaccine trial who were seronegative at baselin

272 In Bolivia, monovalent rotavirus vaccine was introduced in 2008 and a previous

273 The monovalent rotavirus vaccine was introduced in Tanzania on 1 Januar

274 Three doses of BRV-PV, an oral rotavirus vaccine, had an efficacy of 66.7% against seve

275 The oral infant rotavirus vaccine, Rotarix, was introduced in England an

276 ntries that were among the early adopters of rotavirus vaccine.

277 Despite successes, oral rotavirus vaccines are less effective in developing coun

278 Rotavirus vaccines are now globally recommended by the W

279 Implementation of rotavirus vaccines has substantially decreased hospitali

280 Two rotavirus vaccines have been licensed in >100 countries

281 level of protection detected for the current rotavirus vaccines in low-income versus high-income sett

282 t lower effectiveness and waning immunity of rotavirus vaccines in resource-poor populations.

283 oncerns remain about the performance of oral rotavirus vaccines in these challenging settings.

284 Efficacy of live oral rotavirus vaccines is reduced in low-income compared wit

285 Parenteral non-replicating rotavirus vaccines might offer benefits over oral vaccin

286 Rotavirus vaccines were initially introduced in Australi

287 In 2006, 2 rotavirus vaccines were licensed.

288 strain replacement after the introduction of rotavirus vaccines, particularly in developing countries

289 Two rotavirus vaccines, Rotarix (RV1) and RotaTeq (RV5), wer

290 protection provided by live attenuated oral rotavirus vaccines.

291 s vaccination coverage using controls from a rotavirus VE test-negative case-control study and to exa

292 nt and cost-effective approach to estimating rotavirus VE through case-control studies.

293 mation of the spatiotemporal distribution of rotavirus VP7 (G) and VP4 (P) genotypes have shown evide

294 During entry of rhesus rotavirus, VP8* interacts with cell surface gangliosides

295 Overall, rotavirus was detected in 5.5% (408/7440) of diarrheal s

296 Rotavirus was detected in 75 (28%) of 266 fecal samples

297 Historically, rotavirus was the most common cause of severe disease in

298 To predict the proportion of diarrhea due to rotavirus, we constructed a multiple linear regression m

299 ed in 75 (28%) of 266 fecal samples and P[8] rotaviruses were found to be the predominant genotype.

300 In this study, new variants of G9 rotaviruses were identified in two children with diarrhe